Anti-CD20 Antibody Therapy for B-Cell LymphomasMALONEY, David G.The New England journal of medicine. 2012, Vol 366, Num 21, pp 2008-2016, issn 0028-4793, 9 p.Article

Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 AbGOPAL, Ajay K; PRESS, Oliver W; WILBUR, Shani M et al.Blood. 2008, Vol 112, Num 3, pp 830-835, issn 0006-4971, 6 p.Article

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibodyGOLDENBERG, David M; ROSSI, Edmund A; STEIN, Rhona et al.Blood. 2009, Vol 113, Num 5, pp 1062-1070, issn 0006-4971, 9 p.Article

Anti-CD20 en oncohématologie : Biothérapies = Anti-C020 in hematologic oncologyMILPIED, Noël.La Presse médicale (1983). 2009, Vol 38, Num 5, pp 788-798, issn 0755-4982, 11 p.Article

Acquired hemophilia A: three different presentations of the same diseaseDEL CAMPO, Raquel; BARGAY, Juan; CLADERA, Antonia et al.Blood coagulation & fibrinolysis. 2010, Vol 21, Num 2, pp 188-191, issn 0957-5235, 4 p.Article

Caractéristiques et traitement des anémies hémolytiques auto-immunes et du syndrome d'Evans de l'adulte = Characteristics and management of autoimmune haemolytic anemia and Evans'syndrome in adultsMICHEL, M.La Revue de médecine interne (Paris). 2008, Vol 29, pp 54-60, issn 0248-8663, 7 p., HS1Conference Paper

Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cellsPASCAL, Virginie; LAFFLEUR, Brice; COGNE, Michel et al.Haematologica (Roma). 2012, Vol 97, Num 11, pp 1686-1694, issn 0390-6078, 9 p.Article

Resistant Kawasaki Disease Treated with Anti-CD20SAUVAGET, Emilie; BONELLO, Béatrice; DAVID, Marion et al.The Journal of pediatrics. 2012, Vol 160, Num 5, pp 875-876, issn 0022-3476, 2 p.Article

CD 137 stimulation enhances the antilymphoma activity of anti-CD20 antibodiesKOHRT, Holbrook E; HOUOT, Roch; CHAO, Mark P et al.Blood. 2011, Vol 117, Num 8, pp 2423-2432, issn 0006-4971, 10 p.Article

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphomaROSSI, Edmund A; GOLDENBERG, David M; CARDILLO, Thomas M et al.Blood. 2009, Vol 113, Num 24, pp 6161-6171, issn 0006-4971, 11 p.Article

Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infectionBROWNE, Sarah K; ZAMAN, Rifat; FREEMAN, Alexandra F et al.Blood. 2012, Vol 119, Num 17, pp 3933-3939, issn 0006-4971, 7 p.Article

Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodiesPIEVANI, Alice; BELUSSI, Camilla; KLEIN, Christian et al.Blood. 2011, Vol 117, Num 2, pp 510-518, issn 0006-4971, 9 p.Article

Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasGUPTA, Pankaj; GOLDENBERG, David M; ROSSI, Edmund A et al.Blood. 2010, Vol 116, Num 17, pp 3258-3267, issn 0006-4971, 10 p.Article

Anti-CD20 monoclonal antibodies: historical and future perspectivesLIM, Sean H; BEERS, Stephen A; FRENCH, Ruth R et al.Haematologica (Roma). 2010, Vol 95, Num 1, pp 135-143, issn 0390-6078, 9 p.Article

Is Splenectomy Necessary for Immune Thrombocytopenic Purpura? The Role of Rituximab in Patients With Corticosteroid Resistance in a Single-Center ExperienceCHENG ZHANG; LIU, Huan-Feng; CHEN, Xing-Hua et al.Clinical therapeutics. 2014, Vol 36, Num 3, pp 385-388, issn 0149-2918, 4 p.Article

CD40 stimulation sensitizes CLL cells to rituximab-induced cell deathJAK, M; VAN BOCHOVE, G. G. W; VAN LIER, R. A. W et al.Leukemia. 2011, Vol 25, Num 6, pp 968-978, issn 0887-6924, 11 p.Article

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patientsSALLES, Gilles; MORSCHHAUSER, Franck; PISA, Pavel et al.Blood. 2012, Vol 119, Num 22, pp 5126-5132, issn 0006-4971, 7 p.Article

Construction and Characterization of a Bispecific Anti-CD20 Antibody with Potent Antitumor Activity against B-Cell LymphomaBOHUA LI; XUNMING ZHANG; SHU SHI et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 15, pp 6293-6302, issn 0008-5472, 10 p.Article

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibodyBLEEKER, Wim K; MUNK, Martin E; MACKUS, Wendy J. M et al.British journal of haematology. 2008, Vol 140, Num 3, pp 303-312, issn 0007-1048, 10 p.Article

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activationBEERS, Stephen A; CHAN, Claude H. T; JAMES, Sonya et al.Blood. 2008, Vol 112, Num 10, pp 4170-4177, issn 0006-4971, 8 p.Article

A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatmentPRODANOVIC, Edward M; KORMAN, Neil J.Journal of dermatological treatment. 2008, Vol 19, Num 6, pp 368-370, issn 0954-6634, 3 p.Article

Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I studyLIEBMAN, Howard A; SALEH, Mansoor N; BUSSEL, James B et al.British journal of haematology. 2013, Vol 162, Num 5, pp 693-701, issn 0007-1048, 9 p.Article

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular LymphomaFORERO-TORRES, Andres; DE VOS, Sven; SMITH, Mitchell R et al.Clinical cancer research (Print). 2012, Vol 18, Num 5, pp 1395-1403, issn 1078-0432, 9 p.Article

Anti-CD20 monoclonal antibody therapy in multiple myelomaKAPOOR, Prashant; GREIPP, Patricia T; MORICE, William G et al.British journal of haematology. 2008, Vol 141, Num 2, pp 135-148, issn 0007-1048, 14 p.Article

Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignanciesOKROJ, Marcin; ÖSTERBORG, Anders; BLOM, Anna M et al.Cancer treatment reviews. 2013, Vol 39, Num 6, pp 632-639, issn 0305-7372, 8 p.Article